CLNNW

Clene Inc. is a clinical-stage pharmaceutical firm dedicated to the discovery, development, and market introduction of innovative therapeutic agents derived from clean-surfaced nanotechnology (CSN). The company's primary drug candidate, CNM-Au8, is currently undergoing extensive clinical evaluation for various neurological conditions. For Amyotrophic Lateral Sclerosis (ALS), it's being tested in a pivotal Phase 2/3 registrational clinical trial, building on a previously completed Phase 2 "proof-of-concept" study in patients with early symptomatic ALS. Further research includes two finished open-label, investigator-blinded Phase 2 trials that explored its effects on brain energy metabolites. CNM-Au8 has also completed a Phase 2 trial focused on addressing visual pathway deficits in chronic optic neuropathy, aiming to promote remyelination in individuals with stable relapsing Multiple Sclerosis. Another Phase 2 trial is also targeting Parkinson's Disease patients. Beyond its flagship candidate, Clene's portfolio features CNM-AgZn17, a gel polymer suspension containing silver and zinc ions, which is under development for treating infectious diseases and supporting wound healing. Additionally, the company offers CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent designed to combat various infections, including conditions like COVID-19, and to bolster immune responses for symptom relief. Clene also markets and distributes dietary supplements, specifically rMetx, a liquid supplement featuring zinc-silver ions, and KHC46, a liquid gold supplement with ultra-low concentrations of gold nanoparticles. The company maintains its headquarters in Salt Lake City, Utah.